AGL 23.54 Increased By ▲ 0.60 (2.62%)
AIRLINK 111.26 Decreased By ▼ -0.03 (-0.03%)
BOP 5.29 Increased By ▲ 0.04 (0.76%)
CNERGY 3.72 No Change ▼ 0.00 (0%)
DCL 8.10 Increased By ▲ 0.11 (1.38%)
DFML 43.75 Increased By ▲ 3.48 (8.64%)
DGKC 88.25 Increased By ▲ 0.25 (0.28%)
FCCL 22.06 Increased By ▲ 0.07 (0.32%)
FFBL 42.30 Increased By ▲ 0.10 (0.24%)
FFL 8.89 Increased By ▲ 0.34 (3.98%)
HUBC 152.65 Decreased By ▼ -0.64 (-0.42%)
HUMNL 10.56 Increased By ▲ 0.11 (1.05%)
KEL 4.52 Increased By ▲ 0.02 (0.44%)
KOSM 3.82 Decreased By ▼ -0.03 (-0.78%)
MLCF 36.98 Increased By ▲ 0.18 (0.49%)
NBP 48.20 Increased By ▲ 0.21 (0.44%)
OGDC 132.60 Increased By ▲ 0.80 (0.61%)
PAEL 26.60 Increased By ▲ 0.45 (1.72%)
PIBTL 6.02 Decreased By ▼ -0.01 (-0.17%)
PPL 116.50 Increased By ▲ 1.00 (0.87%)
PRL 22.72 Increased By ▲ 0.12 (0.53%)
PTC 12.55 Decreased By ▼ -0.03 (-0.24%)
SEARL 55.75 Increased By ▲ 0.06 (0.11%)
TELE 7.36 Increased By ▲ 0.16 (2.22%)
TOMCL 38.00 Increased By ▲ 1.00 (2.7%)
TPLP 7.90 Increased By ▲ 0.05 (0.64%)
TREET 15.30 No Change ▼ 0.00 (0%)
TRG 59.96 Increased By ▲ 5.41 (9.92%)
UNITY 31.72 Decreased By ▼ -0.14 (-0.44%)
WTL 1.18 Increased By ▲ 0.01 (0.85%)
BR100 8,398 Increased By 53.2 (0.64%)
BR30 26,535 Increased By 187.1 (0.71%)
KSE100 79,421 Increased By 433.6 (0.55%)
KSE30 25,485 Increased By 119.9 (0.47%)
Business & Finance

Swiss drugmaker Novartis to help make Pfizer-Biontech COVID-19 vaccine

  • Three vaccines from Western companies Pfizer-Biontech, AstraZeneca and Moderna have been approved by regulators.
  • Novartis has been mobilizing on multiple fronts to support the global pandemic response.
Published January 29, 2021

ZURICH: Swiss drugmaker Novartis has signed an initial agreement to provide manufacturing capacity for Pfizer and Biontech's COVID-19 vaccine, a move aimed at helping boost production as supplies fall shy of demand.

Subject to reaching a final agreement, Novartis plans to commence production in the second quarter of 2021, the Basel-based company said on Friday, adding it would use manufacturing facilities at its site in Stein, Switzerland, near the Rhine River on the German border.

Three vaccines from Western companies Pfizer-Biontech, AstraZeneca and Moderna have been approved by regulators, but limited production and delayed deliveries have hampered efforts to quickly vaccinate people most at risk for COVID-19.

Novartis's announcement that it was joining the push to remedy the shortfall follows a move by Sanofi this week to work with Biontech to supply 125 million doses of its mRNA vaccine to the European Union.

"Novartis has been mobilizing on multiple fronts to support the global pandemic response," said Steffen Lang, head of Novartis Technical Operations.

Novartis, which did not give specifics on how much drug substance it would produce for Pfizer-Biontech if the deal goes through, added it is in "advanced discussions" with additional companies to take on production of mRNA, therapeutic protein and other raw materials for vaccines and therapeutics.

Comments

Comments are closed.